Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2/Neu-Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT07557004
What this trial is testing

SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT07394218
What this trial is testing

CtDNA-guided Treatment Decision-making

Who this might be right for
Metastatic Breast Cancer ( HER2 Negative)ctDNA
Fudan University 122
Early research (Phase 1)Ended earlyNCT04042480
What this trial is testing

SGN-CD228A in Advanced Solid Tumors

Who this might be right for
Cutaneous MelanomaPleural MesotheliomaHER2 Negative Breast Neoplasms+3 more
Seagen Inc. 88
Testing effectiveness (Phase 2)Study completedNCT02048059
What this trial is testing

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Who this might be right for
Breast CancerBrain Metastases
Angiochem Inc 72
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Not applicableLooking for participantsNCT06856200
What this trial is testing

Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Who this might be right for
Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
Fudan University 36
Testing effectiveness (Phase 2)Looking for participantsNCT06176534
What this trial is testing

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Who this might be right for
Advanced Breast CancerTreatmentHR Low/HER2 Negative
Henan Cancer Hospital 240
Large-scale testing (Phase 3)Looking for participantsNCT04852887
What this trial is testing

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Who this might be right for
Stage I Breast Cancer
NRG Oncology 1,670
Testing effectiveness (Phase 2)Study completedNCT00773695
What this trial is testing

Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 150
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Study completedNCT02402764
What this trial is testing

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393
What this trial is testing

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Spanish Breast Cancer Research Group 200
Large-scale testing (Phase 3)Ended earlyNCT05207709
What this trial is testing

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 61
Testing effectiveness (Phase 2)Active Not RecruitingNCT06334432
What this trial is testing

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorHER2-negative Breast CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)+2 more
Nuvation Bio Inc. 466
Testing effectiveness (Phase 2)Study completedNCT03890744
What this trial is testing

ModraDoc006/r in Patients With Breast Cancer

Who this might be right for
Metastatic Breast CancerRecurrent Breast Cancer
Modra Pharmaceuticals 12
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Early research (Phase 1)Study completedNCT04541433
What this trial is testing

AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 10
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Looking for participantsNCT05981001
What this trial is testing

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 170
Next Page